Optimizing Pediatric Oncology Denial Management

The Unique Landscape of Pediatric Oncology Denials

Denials in pediatric oncology often stem from the complexity of treatment protocols, the rapid evolution of therapies, and the high cost of care. From multi-agent chemotherapy regimens dictated by COG protocols to novel CAR-T cell therapies and advanced radiation like proton beam therapy, each treatment pathway presents distinct documentation and authorization challenges. Misinterpretation of clinical guidelines or payer-specific medical policies can lead to denials that require expert intervention.

Common Pediatric Oncology Prior Authorization Triggers Leading to Denials

• **Chemotherapy Regimens:** Complex multi-agent protocols, especially those involving off-label indications or novel combinations, frequently trigger clinical necessity denials.
• **CAR-T Therapies:** High-cost, specialized cellular therapies with specific site-of-care requirements often face intense scrutiny, leading to denials based on medical necessity or facility designation.
• **Proton Beam Therapy:** Advanced radiation techniques, while clinically indicated for certain pediatric cancers, can be denied if not precisely aligned with payer-specific coverage criteria or if alternative radiation is deemed sufficient.
• **Off-Label Drug Use:** Many critical medications for childhood cancers are used off-label, necessitating robust documentation and appeals grounded in peer-reviewed literature and NCCN/ASCO guidelines.
• **Genetic Testing & Biomarker Analysis:** Denials for advanced diagnostic testing used to guide targeted therapies are common, requiring appeals that clearly link testing to treatment strategy.

Klivira's Automated Denial Management for Pediatric Oncology

Klivira's platform is engineered to tackle the specific challenges of pediatric oncology denial management. We automate the intake of denials from all channels, including X12 835 transactions for claim denials, X12 277 for PA status, and Da Vinci PAS ClaimResponse for conformant payers. Our system normalizes CARC/RARC codes and payer-specific variations, ensuring accurate categorization and routing of denials, from technical issues to complex clinical necessity appeals.

Key Automation Features for Pediatric Oncology Denial Workflows

• **Automated CARC/RARC Normalization:** Standardizes denial reasons across X12 and payer-specific codes, enabling precise routing for pediatric oncology cases.
• **Intelligent Appeal Packet Assembly:** Leverages FHIR integration with EMRs to pull relevant clinical documentation, including updated notes, lab results, and problem lists, to strengthen appeals for high-cost therapies.
• **Timely-Filing Window Enforcement:** Proactively tracks and enforces per-payer appeal deadlines, preventing lost revenue due to missed windows for critical pediatric treatments.
• **Peer-to-Peer Scheduling Integration:** Facilitates the scheduling of peer-to-peer reviews for high-acuity clinical denials, ensuring ordering clinicians can engage effectively.
• **Denial Pattern Reporting:** Identifies recurring denial reasons by payer and treatment type, providing actionable insights to optimize upstream prior authorization submissions for pediatric oncology services.

Mitigating Financial Impact and Improving Patient Access in Pediatric Oncology

By automating denial management, Klivira helps pediatric oncology centers reduce administrative costs and improve revenue capture. Our system addresses common failure modes such as CARC/RARC parsing errors, documentation gaps, and missed timely-filing deadlines, which are particularly costly in high-value pediatric cases. The financial argument for automation is grounded in industry benchmarks like the CAQH Index and MGMA surveys, which highlight the significant rework costs associated with manual denial processes. Ultimately, efficient denial resolution ensures that pediatric patients receive their critical treatments without unnecessary delays.